Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The primary objective of this research study is to evaluate the effect of tirzepatide, relative to placebo, as an adjunct to BUP on retention, substance use, and sleep outcomes in individuals with OUD.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Umiarkowane lub ciężkie uzależnienie od opioidów
- •Rozpoczęcie buprenorfiny niedawno (7-60 dni temu) i przyjmowanie odpowiedniej dawki
- •Gotowość do losowego przydzielenia do grupy otrzymującej tirzepatide lub placebo
- •Możliwość zrozumienia badania i wyrazenia świadomej zgody na uczestnictwo
- •Nie być w ciąży ani nie karmić piersią; jeśli możliwa ciąża, test musi być ujemny
- •Jeśli możliwa ciąża, zgoda na stosowanie skutecznych metod antykoncepcji podczas badania i 30 dni po nim
- •Zdolność uczestniczenia w cotygodniowych wizytach przez 6 miesięcy
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 17, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (9)
Gateway Community Services
Jacksonville, United States
IBIS Behavioral Health
Tampa, United States
Ruth M. Rothstein CORE Center
Chicago, United States
The Gibson Center for Behavioral Change
Cape Girardeau, United States
Prisma Health
Greenville, United States
Vanderbilt University Medical Center
Nashville, United States
University of Utah
Salt Lake City, United States
Marshall Health
Huntington, United States
Healthy Minds/Chestnut Ridge
Morgantown, United States
Trial contact
Frankie B Kropp, MS, LICDC
Benjamin T Kropp, MSLS
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/18/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.